Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00439140 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
A Phase 3 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
NCT00439140: Clinical Trial Phase 3 study, sponsored by Allergan.
NCT00439140 is a Phase 3 study that was terminated before completion, run by Allergan. The registered enrollment target is 41 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00439140, a Phase 3 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.
Primary Outcome
Spirometry was conducted according to American Thoracic Society standards. A spirometer was used to measure FVC, the maximum amount of air exhaled from the lungs after taking the deepest breath possible, at Baseline and Week 6. A positive change from Baseline indicated improvement.
Interventions
- DRUG Normal Saline (Placebo)
- BIOLOGICAL botulinum toxin Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Why NCT00439140 stopped before completion
NCT00439140 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Normal Saline (Placebo) is the first listed.
NCT00439140 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00439140 about?
NCT00439140 is a clinical study titled "Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder". This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.
What is the current status of trial NCT00439140?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2007-06. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00439140?
The interventions under investigation include: Normal Saline (Placebo) (DRUG), botulinum toxin Type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT00439140?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00439140's enrollment target sits among peer trials
41 1877th of 2000 higher than 123 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia